Prevention of prostate‐cancer metastasis in vivo by a novel synthetic inhibitor of urokinase‐type plasminogen activator (uPA)

Keyphrases

• Prostate Cancer 100%
• Metastasis 100%
• Plasminogen Activator 100%
• Synthetic Inhibitors 100%
• Tumor Metastasis 66%
• Tumor Growth 50%
• Plasminogen Activator inhibitor-1 (PAI-1) 33%
• Tumor Invasiveness 33%
• Experimental Animals 33%
• Primary Tumor Volume 33%
• Kidney 16%
• Overexpressing 16%
• Renal Function 16%
• Overexpression 16%
• Lung 16%
• Invasiveness 16%
• Enzymatic Activity 16%
• Adverse Effects 16%
• Spleen 16%
• Lymph Node 16%
• Serine Protease 16%
• Inoculation 16%
• Selective Inhibitor 16%
• Nephrotoxicity 16%
• Tissue Remodeling 16%
• Vehicle Control 16%
• Syngeneic Model 16%
• Large Tumors 16%
• Benzo 16%
• Histological Examination 16%
• Matrix Degradation 16%
• Tumor Weight 16%
• Rat Prostate 16%
• Experimental Cells 16%
• Osteoblastic 16%
• Copenhagen Rat 16%
• Pathogenetic Factors 16%
• Skeletal Lesions 16%
• Skeletal Site 16%

Immunology and Microbiology

• Cell Line 100%
• Tumor Volume 100%
• Experimental Animal 100%
• Prostate 50%
• Enzyme Activity 50%
• Kidney Function 50%
• Syngenic 50%
• Flank 50%
• Copenhagen Rat 50%
• Lymph Node 50%
• Serine 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Plasminogen Activator 100%
• Tumor Growth 50%
• Experimental Animal 33%
• Prostate Cancer 33%
• Plasminogen Activator Inhibitor 33%
• Primary Tumor 33%
• Nephrotoxicity 16%
• Copenhagen Rat 16%
• Bone Lesion 16%
• Serine Proteinase 16%
• Neoplasm 16%